Ocular Hypertension

The FDA has approved an abbreviated new drug application for travoprost ophthalmic solution 0.004%, Alembic Pharmaceuticals announced in a press release.

Combining cataract surgery with minimally invasive MIGS leads to more efficient IOP lowering and reduced need for medications than phacoemulsification alone, according to a study.

Aerie Pharmaceuticals has submitted a marketing authorization application for Roclanda to the European Medicines Agency, according to a press release.

A marketing authorization for Rhokiinsa, for the reduction of elevated IOP in open-angle glaucoma or ocular hypertension, has been approved by the European Commission, according to a press release.

Ocular Therapeutix will restructure its operations, resulting in approximately $11 million in annualized savings, according to a press release.

SAN FRANCISCO — A study showed Bimatoprost sustained-release implant was noninferior to timolol and may potentially provide sustained IOP control for patients with open-angle glaucoma or ocular hypertension, according to a speaker here.

Goniotomy with Kahook Dual Blade may be considered first as treatment in certain patients with glaucoma, according to a study.

The combination of netarsudil and latanoprost proved to be superior in treating glaucoma compared with the use of the two drugs by themselves, according to findings published in the American Journal of Ophthalmology.

Primary open-angle glaucoma was found to be associated with lower plasmatic nicotinamide levels, and researchers suggest that the vitamin may have future therapeutic use.

Earlier this year, The Lancet published the results of the LiGHT trial, comparing selective laser trabeculoplasty and eye drops to treat patients with open-angle glaucoma, which found SLT provided more robust IOP lowering while being a more cost-efficient first-line treatment.